33.57

2.32% 0.76

After Hours: 33.60 0.03 +0.09%

Urogen Pharma Ltd (URGN)

Overview News Price History Option Chain Financials Discussions Forecast

Urogen Pharma Ltd stock is traded at $33.57, with a volume of 834.76K. It is up +2.32% in the last 24 hours and up +17.46% over the past month. UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.

Previous Close:

$32.81

Open:

$33.45

24h Volume:

834.76K

Relative Volume:

1.07

Market Cap:

$1.64B

Revenue:

$109.79M

Net Income/Loss:

$-153.49M

P/E Ratio:

-10.46

EPS:

-3.2098

Net Cash Flow:

$-172.59M

1W Performance:

+13.80%

1M Performance:

+17.46%

6M Performance:

+54.56%

1Y Performance:

+125.76%

1-Day Range:

$32.21

$33.79

1-Week Range:

$29.32

$33.79

52-Week Range:

$12.73

$33.79

Urogen Pharma Ltd Stock (URGN) Company Profile

Name

Urogen Pharma Ltd

Sector

Healthcare (1104)

Industry

Biotechnology (617)

Phone

972 9 770 7601

Address

9 HA'TA'ASIYA ST, RA'ANANA

Employee

291

Twitter

@UroGenPharma

Next Earnings Date

2026-08-06

Latest SEC Filings

URGN's Discussions on Twitter

Compare URGN vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
URGN Urogen Pharma Ltd	33.57	1.60B	109.79M	-153.49M	-172.59M	-3.2098
VRTX Vertex Pharmaceuticals Inc	451.63	116.49B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	609.94	63.73B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.72	55.49B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	278.09	37.75B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	162.99	33.54B	742.00K	-1.37B	-1.07B	-7.0731

Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-10-26	Initiated	Jefferies	Buy
Aug-19-25	Initiated	Piper Sandler	Overweight
Jun-16-25	Upgrade	H.C. Wainwright	Neutral → Buy
May-22-25	Downgrade	H.C. Wainwright	Buy → Neutral
Apr-16-25	Initiated	Scotiabank	Sector Outperform
Feb-19-25	Resumed	Ladenburg Thalmann	Buy
Aug-22-24	Initiated	Guggenheim	Buy
Feb-08-23	Downgrade	Jefferies	Buy → Hold
Apr-27-22	Initiated	Berenberg	Buy
Apr-16-20	Reiterated	H.C. Wainwright	Buy
Apr-13-20	Reiterated	H.C. Wainwright	Buy
Jan-09-20	Initiated	National Securities	Neutral
May-30-19	Initiated	JP Morgan	Neutral
May-29-19	Initiated	Goldman	Neutral
Jan-29-19	Initiated	H.C. Wainwright	Buy
Nov-08-18	Resumed	Jefferies	Buy
Apr-04-18	Upgrade	Raymond James	Mkt Perform → Outperform
Jan-02-18	Initiated	Ladenburg Thalmann	Buy
Nov-15-17	Reiterated	Oppenheimer	Outperform
Nov-15-17	Downgrade	Raymond James	Outperform → Mkt Perform

View All

Urogen Pharma Ltd Stock (URGN) Latest News

Jun 18, 2026

Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares? - AOL.com

Jun 18, 2026

(URGN) Risk Channels and Responsive Allocation - Stock Traders Daily

Jun 18, 2026

Urogen Pharma stock hits 52-week high at 32.5 USD By Investing.com - Investing.com Nigeria

Jun 18, 2026

Jun 17, 2026